Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Company Overview

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Key Stats

• Today's Range: $0.30 to $0.33
• 50-Day Range: $0.25 to $0.50
• 52-Week Range: $0.22 to $2.27
• Volume: 210,982 shs
• Average Volume: 1.95 million shs
• Market Capitalization: $3.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Petros Pharmaceuticals Stock Analysis - MarketRank™

Petros Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Petros Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Petros Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Petros Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Petros Pharmaceuticals has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.08% of the float of Petros Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Petros Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Petros Pharmaceuticals has recently increased by 139.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Petros Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Petros Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.08% of the float of Petros Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Petros Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Petros Pharmaceuticals has recently increased by 139.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for PTPI on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.25% of the stock of Petros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.34% of the stock of Petros Pharmaceuticals is held by institutions.

PTPI Stock Analysis - Frequently Asked Questions

How have PTPI shares performed this year?

Petros Pharmaceuticals' stock was trading at $0.3939 at the start of the year. Since then, PTPI stock has decreased by 18.8% and is now trading at $0.32.
View the best growth stocks for 2025 here.

When did Petros Pharmaceuticals' stock split?

Petros Pharmaceuticals's stock reverse split on Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Petros Pharmaceuticals?

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Petros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Today: 1/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTPI
• CUSIP: N/A
• CIK: 1815903
• Web: www.petrospharma.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,160,000.00
• Net Margins: N/A
• Pretax Margin: -117.50%
• Return on Equity: -78.22%
• Return on Assets: -23.50%

Debt

• Debt-to-Equity Ratio: 1.58
• Current Ratio: 0.85
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: $5.82 million
• Price / Sales: 0.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 10,020,000
• Free Float: 8,788,000
• Market Cap: $3.21 million
• Optionable: Not Optionable
• Beta: 1.85